Dogwood Therapeutics Inc.
Organization details
- Legal name
- Dogwood Therapeutics Inc.
- Former names
- Virios Therapeutics, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Alpharetta
- Headquarters state / province
- Georgia
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- DWTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001818844
- EIN
- 85-4314201
Board of directors
-
David R. Keefer · DirectorSince 2023
-
Gregory Scott Duncan · Director · CHIEF EXECUTIVE OFFICERSince 2023
-
John C. Thomas · DirectorSince 2023
-
Kean Meng Melvin Toh · DirectorSince 2024
-
La Rosa Abel De · DirectorSince 2023
-
Richard Alan Burch · DirectorSince 2023
-
Richard James Whitley · DirectorSince 2023
-
William Pridgen · DirectorSince 2023
-
Ying Choi Alan Abel Yu · DirectorSince 2024
Chief executives
Director election results
Annual meeting of June 16, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
100.0%
-
100.0%
-
100.0%
-
100.0%
Board connections
1 of this board's directors also sit on 1 other board. 1 is in the same sector.
-
CorMedix Inc. Same sectorvia Gregory Scott Duncan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 26, 2026 | Sealbond Ltd Director, 10% owner, See Remarks | Grant or award | +4,098,360 | $1.22 | $4,999,999 |
| Nov 21, 2025 | Conjoint Inc. Director, 10% owner, See Remarks | Derivative conversion | +21,610,950 | — | — |
| Nov 21, 2025 | Conjoint Inc. Director, 10% owner, See Remarks | Derivative conversion | +2,842,638 | — | — |
| Aug 21, 2023 | William Pridgen Director | Open-market purchase | +15,335 | $1.30 | $19,936 |
| Aug 17, 2023 | Gregory Scott Duncan Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market purchase | +25,000 | $1.25 | $31,250 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Dogwood Therapeutics Inc.
Who is the CEO of Dogwood Therapeutics Inc.?
Gregory Scott Duncan is Dogwood Therapeutics Inc.'s CHIEF EXECUTIVE OFFICER.
How many directors are on Dogwood Therapeutics Inc.'s board?
Dogwood Therapeutics Inc.'s board has 9 directors: David R. Keefer, Gregory Scott Duncan, John C. Thomas, Kean Meng Melvin Toh, La Rosa Abel De, Richard Alan Burch, Richard James Whitley, William Pridgen and Ying Choi Alan Abel Yu.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="dogwood-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.